Prior to creating the oral vaccine, UTMB researchers developed three vaccine candidates from genetically mutated Salmonella Typhimurium. These potential vaccines were administered to mice via injection and protected the rodents against a lethal dose of Salmonella, producing a robust immune response. However, an oral vaccine would be the least invasive and likely the most effective method of protection from Salmonella bacteria in humans. An oral vaccine would share the same ingestion pathway the bacteria use to harm the digestive system.
“In the current study, we analyzed the immune responses of mice that received the vaccination by mouth as well as how they responded to a lethal dose of Salmonella,” said Ashok Chopra, PhD, one of the study’s authors and UTMB professor of microbiology and immunology. “We found that the orally administered vaccines produced strong immunity against Salmonella, showing their potential for future use in people.”
Currently, there is no vaccine available for Salmonella poisoning. Antibiotics provide a line of defense from the bacteria, but some strains of Salmonella are developing antibiotic resistance.
According to the CDC, Salmonella causes approximately 1.4 million infections annually in the U.S., resulting in 400 deaths every year.
More articles on infection control:
FDA approves new 1-hour MRSA test
California sees almost 20k reports of HAIs in 2015: 5 report findings
How should hospitals respond to outbreaks? SHEA, CDC to develop resources
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
